Back to perspectives

Robotics Industry and Public Markets

After Unitree’s Listing, Investors Should Look Beyond the Robot Demonstrations

After Unitree’s Listing, Investors Should Look Beyond the Robot Demonstrations

Humanoid robots make compelling visual news, but a listed company's value ultimately depends on product revenue, gross margin, R&D efficiency, supply-chain execution and cash flow. Unitree Robotics' listing provides a public evidence base that is more useful than the concept alone.

Public-market review

Demonstrations attract attention; orders, margins and cash flow determine value

RMB1.699bn

Unitree Robotics' 2025 revenue

RMB278m

2025 net profit attributable to shareholders of the parent

>35%

Overseas revenue share disclosed in public filings

01

Separate the listing facts from the market narrative

Shanghai Stock Exchange disclosures show that A shares of Hangzhou Unitree Robotics Co., Ltd. began trading on August 19, 2026 under stock code 688836. Total shares outstanding after the listing were approximately 404.46 million, of which about 30.088 million entered initial public circulation.

This article does not use valuations, orders or future shipment figures that are not confirmed in company or exchange filings. A listing brings a company into the public market; it does not mean that every barrier to robotics commercialisation has been crossed.

02

Revenue is no longer confined to quadruped robots

Audited figures show revenue of approximately RMB1.699 billion in 2025, RMB393 million in 2024 and RMB159 million in 2023. Net profit attributable to shareholders of the parent was approximately RMB278 million in 2025 and RMB95 million in 2024, following a loss of about RMB11 million in 2023.

Principal-business revenue in 2025 was approximately RMB1.676 billion: humanoid robots contributed about RMB868 million, quadruped robots RMB698 million, components RMB104 million, and other principal businesses RMB7 million. Humanoid products are clearly part of the revenue mix, but that alone does not prove that the end market is mature.

Unitree Robotics’ revenue and net profit from 2023 to 2025
Unitree Robotics’ revenue and net profit from 2023 to 2025
03

Three questions behind the high growth

First, is demand driven by repeatable production use, or largely by research, demonstrations and early pilots? Second, can hardware growth support after-sales service, reliability and safety costs? Third, could policy risk in the supply chain and overseas markets affect delivery?

The prospectus explicitly notes that the energy systems, computing, batteries, durability and ecosystem for humanoid robots have not yet been validated at scale. Overseas revenue exceeds 35%, while some imported materials are exposed to trade-restriction risks.

The company forecast first-half 2026 revenue of RMB1.052–1.128 billion, up approximately 35.62%–45.41% year on year. Yet adjusted net profit excluding non-recurring items was expected to fall approximately 6.43%–21.97%, primarily because period expenses such as R&D increased rapidly. Revenue growth and profit growth need not move together.

Main business income structure in 2025
Main business income structure in 2025
04

G70 perspective: turn the robotics narrative into verifiable order economics

For family investors, Unitree Robotics is a useful window into China's embodied-AI industry, but it should not be valued only by video popularity or a single shipment figure. More useful quarterly evidence includes customer repeat purchases, use cases, post-delivery failure and service costs, R&D capitalisation policy, overseas-revenue risk, and whether free cash flow keeps pace with revenue.

05

Important notice

This article is for general information and education only and is not investment advice concerning Unitree Robotics or any security. Financial figures are compiled from public filings; rounding may create minor differences.

G70

G70 investment lens

Turn the robotics narrative into verifiable order economics

Product mix, customer concentration, supply chains, after-sales obligations and free cash flow are the evidence that must be updated after listing.

  1. How are revenue, gross margin and delivery cycles changing across humanoid and quadruped robots?
  2. Can R&D spending translate into production efficiency and repeat orders?
  3. What channel, compliance and after-sales risks accompany overseas revenue?
Sources